• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Atara Biotherapeutics Provides Regulatory Update On Tabelecleucel

    BUSINESSWIRE

    Atara Rises On FDA Inconsistency Causing Cell Therapy Rejection

    BIOSPACE

    Atara Bio Reports Q3 Financials & Operational Advancements

    BUSINESSWIRE

    Pierre Takes Over Tabelecleucel Drug Application from Atara Bio

    PR NEWSWIRE

    Atara Biotherapeutics Updates on Tabelecleucel (Tab-cel®)

    BUSINESSWIRE

    Atara Biotherapeutics Announces Pricing of $16 Million Offering

    BUSINESSWIRE

    Atara Biotherapeutics Q1 Financial Results and Progress

    BUSINESSWIRE

    Atara lays off more staff despite FDA lifting clinical hold

    FIERCE BIOTECH

    Atara Biotherapeutics Updates on Ebvallo Regulatory Status

    BUSINESSWIRE

    Atara Bio Announces Q4 & Full Year 2024 Financial Results

    BUSINESSWIRE

    Atara hit with cell therapy clinical hold after FDA inspection

    FIERCE PHARMA

    Atara Biotherapeutics to Participate at Evercore ISI HealthCONx

    BUSINESSWIRE

    Atara Bio Reports Q3 2024 Financials & Operational Updates

    BUSINESSWIRE

    Atara Bio to Announce Q 32024 Financial Results on Nov 12, 2024

    BUSINESSWIRE

    Atara Reports Inducement Grant Under Nasdaq LR 5635(c)(4)

    BUSINESSWIRE

    Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Rule

    BUSINESSWIRE

    Atara Biotherapeutics to Join H.C. Wainwright 26th Annual Investment Conference

    BUSINESSWIRE

    Atara Biotherapeutics To Participate In Canaccord Genuity Growth Conference

    BUSINESSWIRE

    FDA Accepts Atara`s BLA For Tab-cel With Priority Review

    BUSINESSWIRE

    Atara Presents Preclinical ATA3219 CAR-T Data For Autoimmune Diseases

    BUSINESSWIRE

    Atara Submits Tab-cel BLA For Transplant Lymphoproliferative Disease

    BUSINESSWIRE

    Pierre Fabre announces the submission by Atara of Tabelecleucel (Tab-cel®)

    PR NEWSWIRE

    Atara Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219

    BUSINESSWIRE

    Atara`s stock sinks as MS cell therapy fails in phase 2

    FIERCE BIOTECH

    Atara Announces Plans to Submit Tab-cel BLA in Q2 2024

    BUSINESSWIRE

    Atara to Participate in Cell Therapies in Autoimmune Panel Discussion

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.